NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
uniQure N.v. QURE
12 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 16.1M
Revenue, FY2025 · full 12-year series below
Revenue $M
Net income $M
FY2025 · Revenue 16.1 · Net income -199.0
Compound annual growth
Revenue compounded at −15.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−1236 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -1151.4% · Net -1236.0%
ROE
FY2025 · ROE -207.1%
Each USD of equity lost 207 cents this year.
The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.1 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.2 | −0.2 | −0.3 | −0.1 | 0.3 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | −0.2 | −0.2 | −0.3 | −0.1 | 0.3 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| Income tax $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | · | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 |
| Net income $B | −0.2 | −0.2 | −0.3 | −0.1 | 0.3 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| Free cash flow $B | −0.2 | −0.2 | −0.2 | −0.2 | 0.3 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 |
| EPS, diluted $ | −3.46 | −4.92 | −6.47 | −2.71 | 7.04 | −2.81 | −3.11 | −2340.00 | −2940.00 | −2.93 | −3.72 | −2.91 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −207.1 | −238.5 | −90.2 | −23.7 | 78.5 | −44.1 | −49.4 | −61.9 | −103.6 | −76.6 | −96.3 | −116.8 |
| Shares out B | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 46 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 39 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2014